Diabetes 53:2060-2066, 2004
© 2004 by the American Diabetes Association, Inc.
Interactions Between Endothelin and Nitric Oxide in the Regulation of Vascular Tone in Obesity and Diabetes
Kieren J. Mather1,
Amale Lteif1,
Helmut O. Steinberg1, and
Alain D. Baron1,2
1 Division of Endocrinology & Metabolism, Indiana University School of Medicine, Indianapolis, Indiana
2 Amylin Pharmaceuticals, San Diego, California
Endothelial dysfunction reflects an imbalance of vasodilators and vasoconstrictors. Endogenous endothelin activity seems to be increased in human obesity and type 2 diabetes, and cellular studies suggest that this factor may itself reduce bioavailable nitric oxide (NO). We studied 20 lean, 20 obese, and 14 type 2 diabetic individuals under three protocols, measuring leg vascular responses to intra-arterial infusions of NG-monomethyl-L-arginine (L-NMMA; an inhibitor of NO synthase) alone or in combination with BQ123 (an antagonist of type A endothelin receptors) or phentolamine (used as a control vasodilator). NO synthase inhibition alone (study 1) produced an 40% increase in leg vascular resistance (LVR) in all three participant groups, which was not statistically different across groups (increase in LVR: lean, 135 ± 28; obese, 140 ± 32; type 2 diabetic, 184 ± 51 units; NS). By design, BQ123 at the infused rate of 3 µmol/min produced equivalent 35% reductions in LVR across groups. The subsequent addition of L-NMMA produced a greater increase in LVR among obese participants than lean or type 2 diabetic participants (study 2: lean, 182 ± 48; obese, 311 ± 66; type 2 diabetic, 186 ± 40; P = 0.07). Compared with study 1, the effect of L-NMMA was magnified by BQ123 in obese participants but not in lean or type 2 diabetic participants (P = 0.005, study 1 vs. 2; P = 0.03 for group effect). Phentolamine (75 mg/min) produced vasodilation in obese participants comparable to that seen with BQ123 but failed to augment the L-NMMA response. Endothelin antagonism unmasks or augments NO synthesis capacity in obese but not type 2 diabetic participants. This suggests that impaired NO bioavailability as a result of endogenous endothelin may contribute to endothelial dysfunction in obesity, in addition to direct vasoconstrictor effects of endothelin. In contrast, endothelin antagonism alone is insufficient to restore impaired NO bioavailability in diabetes.
Address correspondence and reprint requests to Kieren J. Mather, MD, FRCPC, Division of Endocrinology & Metabolism, Department of Medicine, Indiana University School of Medicine, CL459, 541 North Clinical Dr., Indianapolis, IN 46202. E-mail: kmather{at}iupui.edu

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon
Cardiovascular Actions of Insulin
Endocr. Rev.,
August 1, 2007;
28(5):
463 - 491.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Lteif, P. Vaishnava, A. D. Baron, and K. J. Mather
Endothelin Limits Insulin Action in Obese/Insulin-Resistant Humans
Diabetes,
March 1, 2007;
56(3):
728 - 734.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. E. Silver, S. D. Beske, D. D. Christou, A. J. Donato, K. L. Moreau, I. Eskurza, P. E. Gates, and D. R. Seals
Overweight and Obese Humans Demonstrate Increased Vascular Endothelial NAD(P)H Oxidase-p47phox Expression and Evidence of Endothelial Oxidative Stress
Circulation,
February 6, 2007;
115(5):
627 - 637.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Loghin, S. Sdringola, and K. L. Gould
Does coronary vasodilation after adenosine override endothelin-1-induced coronary vasoconstriction?
Am J Physiol Heart Circ Physiol,
January 1, 2007;
292(1):
H496 - H502.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. H. Rosa Jr., T. W. Hein, Z. Yuan, W. Xu, M. I. Pechal, R. L. Geraets, J. M. Newman, and L. Kuo
Brimonidine evokes heterogeneous vasomotor response of retinal arterioles: diminished nitric oxide-mediated vasodilation when size goes small
Am J Physiol Heart Circ Physiol,
July 1, 2006;
291(1):
H231 - H238.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-a Kim, M. Montagnani, K. K. Koh, and M. J. Quon
Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms
Circulation,
April 18, 2006;
113(15):
1888 - 1904.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Potenza, F. L. Marasciulo, D. M. Chieppa, G. S. Brigiani, G. Formoso, M. J. Quon, and M. Montagnani
Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production
Am J Physiol Heart Circ Physiol,
August 1, 2005;
289(2):
H813 - H822.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A.A. Lteif, K. Han, and K.J. Mather
Obesity, Insulin Resistance, and the Metabolic Syndrome: Determinants of Endothelial Dysfunction in Whites and Blacks
Circulation,
July 5, 2005;
112(1):
32 - 38.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Rahmouni, M. L.G. Correia, W. G. Haynes, and A. L. Mark
Obesity-Associated Hypertension: New Insights Into Mechanisms
Hypertension,
January 1, 2005;
45(1):
9 - 14.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Diabetes Association.
|
|
| |
|